

Giota Touloumi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5244079/publications.pdf>

Version: 2024-02-01

155
papers

15,124
citations

46984

47
h-index

19169

118
g-index

162
all docs

162
docs citations

162
times ranked

24876
citing authors

#	ARTICLE	IF	CITATIONS
1	Rejoinder to "Biased Estimation With Shared Parameter Models in the Presence of Competing Dropout Mechanisms". <i>Biometrics</i> , 2022, 78, 407-408.	0.8	0
2	Opportunistic screening for hypertension: what does it say about the true epidemiology?. <i>Journal of Human Hypertension</i> , 2022, 36, 364-369.	1.0	3
3	HIV continuum of care: bridging cross-sectional and longitudinal analyses. <i>Aids</i> , 2022, 36, 583-591.	1.0	3
4	Thyroid dysfunction in Greece: Results from the national health examination survey EMENO. <i>PLoS ONE</i> , 2022, 17, e0264388.	1.1	3
5	Validation of the Patient Health Questionnaire-4 (PHQ-4) to screen for depression and anxiety in the Greek general population. <i>Journal of Psychosomatic Research</i> , 2022, 160, 110970.	1.2	14
6	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	2.9	8
7	The cost of a late-detected outbreak among people who inject drugs. A modeling study. <i>International Journal of Drug Policy</i> , 2021, 88, 103032.	1.6	2
8	Prevalence of diabetes and pre-diabetes in Greece. Results of the First National Survey of Morbidity and Risk Factors (EMENO) study. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108646.	1.1	6
9	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. <i>Journal of Infectious Diseases</i> , 2021, 224, 2053-2063.	1.9	6
10	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ μ L. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	1.2	8
11	Land Use Regression Modelling of traffic-related noise in Athens, Greece for use in epidemiological studies. <i>ISEE Conference Abstracts</i> , 2021, 2021, .	0.0	0
12	Living in Roma Settlements in Greece: Self-Perceived Health Status, Chronic Diseases and Associated Social Determinants of Health. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8403.	1.2	2
13	HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review. <i>BMC Public Health</i> , 2021, 21, 1699.	1.2	4
14	Prevalence of tobacco smoking and association with other unhealthy lifestyle risk factors in the general population of Greece: Results from the EMENO study. <i>Tobacco Prevention and Cessation</i> , 2021, 7, 1-13.	0.2	6
15	Could the 2010 HIV outbreak in Athens, Greece have been prevented? A mathematical modeling study. <i>PLoS ONE</i> , 2021, 16, e0258267.	1.1	1
16	Prevalence, awareness, treatment and control of hypertension in Greece: EMENO national epidemiological study. <i>Journal of Hypertension</i> , 2021, 39, 1034-1039.	0.3	8
17	In Vitro Gene Transcription of <i>Listeria monocytogenes</i> After Exposure to Human Gastric and Duodenal Aspirates. <i>Journal of Food Protection</i> , 2020, 83, 89-100.	0.8	4
18	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2905-2916.	2.9	16
20	High prevalence of cardiovascular risk factors in adults living in Greece: the EMENO National Health Examination Survey. <i>BMC Public Health</i> , 2020, 20, 1665.	1.2	21
21	What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts. <i>HIV Medicine</i> , 2020, 21, 3-16.	1.0	15
22	Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece. <i>PLoS ONE</i> , 2020, 15, e0230730.	1.1	24
23	Remdesivir for the Treatment of Covid-19 – Final Report. <i>New England Journal of Medicine</i> , 2020, 383, 1813-1826.	13.9	5,834
24	Design and Development of a Viral Hepatitis and HIV Infection Screening Program (Hprolipsis) for the General, Greek Roma, and Migrant Populations of Greece: Protocol for Three Cross-Sectional Health Examination Surveys. <i>JMIR Research Protocols</i> , 2020, 9, e13578.	0.5	5
25	Misspecifying the covariance structure in a linear mixed model under MAR dropout. <i>Statistics in Medicine</i> , 2020, 39, 3027-3041.	0.8	1
26	Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 951-963.	5.2	99
27	Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?. <i>Aids</i> , 2019, 33, 133-143.	1.0	20
28	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus coinfected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1224-1228.	1.0	15
29	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	1.6	75
30	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019, 38, 2428-2446.	0.8	13
31	Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy. <i>Aids</i> , 2019, 33, 1645-1655.	1.0	12
32	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , 2019, 33, 327-337.	1.0	5
33	HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. <i>BMC Medicine</i> , 2019, 17, 4.	2.3	43
34	Longitudinal and Time-to-Drop-Out Joint Models Can Lead to Seriously Biased Estimates When the Drop-Out Mechanism is at Random. <i>Biometrics</i> , 2019, 75, 58-68.	0.8	14
35	Determining the likely place of HIV acquisition for migrants in Europe combining subject-specific information and biomarkers data. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1979-1997.	0.7	15
36	National Survey of Morbidity and Risk Factors (EMENO): Protocol for a Health Examination Survey Representative of the Adult Greek Population. <i>JMIR Research Protocols</i> , 2019, 8, e10997.	0.5	14

#	ARTICLE	IF	CITATIONS
37	Psychotic (delusional) depression and suicidal attempts: a systematic review and meta-analysis. Acta Psychiatrica Scandinavica, 2018, 137, 18-29.	2.2	56
38	Predictors of <scp>CD</scp>4 cell recovery following initiation of antiretroviral therapy among <scp>HIV</scp>-positive patients with well-estimated dates of seroconversion. HIV Medicine, 2018, 19, 184-194.	1.0	41
39	HIV cascade of care in Greece: Useful insights from additional stages. PLoS ONE, 2018, 13, e0207355.	1.1	11
40	Psychotic (delusional) depression and completed suicide: a systematic review and meta-analysis. Annals of General Psychiatry, 2018, 17, 39.	1.2	41
41	The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort. PLoS ONE, 2018, 13, e0203601.	1.1	4
42	Substantial Heterogeneity in Progress Toward Reaching the 90-90-90 HIV Target in the WHO European Region. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 28-37.	0.9	29
43	Barriers to health care services for migrants living with HIV in Spain. European Journal of Public Health, 2018, 28, 451-457.	0.1	23
44	HIV testing history and access to treatment among migrants living with HIV in Europe. Journal of the International AIDS Society, 2018, 21, e25123.	1.2	27
45	Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. Digestive Diseases and Sciences, 2017, 62, 1363-1372.	1.1	4
46	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV, 2017, 4, e251-e259.	2.1	10
47	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	2.9	44
48	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. Clinical Infectious Diseases, 2017, 64, 1644-1656.	2.9	46
49	Treatment cascade of hepatitis B and C in general, migrant and Roma populations. Journal of Hepatology, 2017, 66, S71-S72.	1.8	3
50	High levels of postmigration HIV acquisition within nine European countries. Aids, 2017, 31, 1979-1988.	1.0	105
51	Higher rates of triple-class virological failure in perinatally <scp>HIV</scp>-infected teenagers compared with heterosexually infected young adults in Europe. HIV Medicine, 2017, 18, 171-180.	1.0	45
52	A randomized trial comparing concise and standard consent forms in the START trial. PLoS ONE, 2017, 12, e0172607.	1.1	28
53	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. Journal of Antimicrobial Chemotherapy, 2017, 72, 2862-2868.	1.3	5
54	A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations. Clinical Infectious Diseases, 2017, 65, 1127-1135.	2.9	10

#	ARTICLE	IF	CITATIONS
55	Factors Associated With Access to HIV Testing and Primary Care Among Migrants Living in Europe: Cross-Sectional Survey. <i>JMIR Public Health and Surveillance</i> , 2017, 3, e84.	1.2	19
56	Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. <i>Hepatology</i> , 2016, 63, 1481-1492.	3.6	215
57	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	2.9	20
58	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
59	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	0.9	43
60	Advancing Migrant Access to Health Services in Europe (AMASE): Protocol for a Cross-sectional Study. <i>JMIR Research Protocols</i> , 2016, 5, e74.	0.5	16
61	Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study. <i>Hippokratia</i> , 2016, 20, 214-221.	0.3	1
62	Boosted Lopinavirâ€“ Versus Boosted Atazanavirâ€“Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2015, 60, 1262-1268.	2.9	6
63	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV,the</i> , 2015, 2, e335-e343.	2.1	52
64	Hepatocellular carcinoma risk in <scp>HB</scp>eAgâ€“negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. <i>Journal of Viral Hepatitis</i> , 2015, 22, 120-127.	1.0	38
65	Performance of the marginal structural models under various scenarios of incomplete marker's values: A simulation study. <i>Biometrical Journal</i> , 2015, 57, 254-270.	0.6	13
66	Delayed HIV diagnosis and initiation of antiretroviral therapy. <i>Aids</i> , 2014, 28, 2297-2306.	1.0	39
67	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. <i>Lancet HIV,the</i> , 2014, 1, e119-e126.	2.1	32
68	Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. <i>Lancet HIV,the</i> , 2014, 1, e41-e48.	2.1	17
69	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	2.9	140
70	What is the impact of systematically missing exposure data on air pollution health effect estimates?. <i>Air Quality, Atmosphere and Health</i> , 2014, 7, 415-420.	1.5	5
71	Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. <i>Hippokratia</i> , 2014, 18, 57-64.	0.3	5
72	Acute effects of ambient ozone on mortality in Europe and North America: results from the APHENA study. <i>Air Quality, Atmosphere and Health</i> , 2013, 6, 445-453.	1.5	87

#	ARTICLE	IF	CITATIONS
73	Performance of parametric survival models under non-random interval censoring: A simulation study. <i>Computational Statistics and Data Analysis</i> , 2013, 63, 16-30.	0.7	1
74	Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study. <i>Journal of Hepatology</i> , 2013, 59, 949-956.	1.8	107
75	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. <i>Clinical Infectious Diseases</i> , 2013, 56, 888-897.	2.9	88
76	Effect of HIV Type 1 Subtype on Virological and Immunological Response to Combination Antiretroviral Therapy: Evidence for a More Rapid Viral Suppression for Subtype A Than Subtype B-Infected Greek Individuals. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 461-469.	0.5	10
77	Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e69266.	1.1	19
78	Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration. <i>PLoS ONE</i> , 2013, 8, e71174.	1.1	12
79	Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. <i>Clinical Infectious Diseases</i> , 2012, 54, 111-118.	2.9	16
80	Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals. <i>Journal of Chemotherapy</i> , 2012, 24, 38-47.	0.7	2
81	Practical methods for competing risks data: A review. <i>Statistical Methods in Medical Research</i> , 2012, 21, 257-272.	0.7	99
82	Differences in HIV Natural History among African and Non-African Seroconverters in Europe and Seroconverters in Sub-Saharan Africa. <i>PLoS ONE</i> , 2012, 7, e32369.	1.1	30
83	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , 2012, 26, 1691-1705.	1.0	31
84	Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. <i>Gut</i> , 2011, 60, 1109-1116.	6.1	159
85	Haemoglobin and Anaemia in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 329-337.	0.6	12
86	Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm ³ : Assessment of Need Following Changes in Treatment Guidelines. <i>Clinical Infectious Diseases</i> , 2011, 53, 817-825.	2.9	180
87	Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. <i>Hippokratia</i> , 2011, 15, 26-31.	0.3	26
88	CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. <i>Aids</i> , 2010, 24, 2697-2704.	1.0	29
89	Modelling competing risks data with missing cause of failure. <i>Statistics in Medicine</i> , 2010, 29, 3172-3185.	0.8	36
90	Analyzing Longitudinal Data in the Presence of Informative Dropout: The Jmre1 Command. <i>The Stata Journal</i> , 2010, 10, 226-251.	0.9	10

#	ARTICLE	IF	CITATIONS
91	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per $\hat{1}$ / $\hat{4}$ L in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.	6.3	82
92	The temporal pattern of mortality responses to ambient ozone in the APHEA project. <i>Journal of Epidemiology and Community Health</i> , 2009, 63, 960-966.	2.0	47
93	Natural course of treated and untreated chronic HCV infection: results of the nationwide <i>Hepnet</i>. <i>Greece</i> cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1121-1130.	1.9	20
94	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. <i>Aids</i> , 2009, 23, 2029-2037.	1.0	64
95	The effect of antiretroviral treatment of different durations in primary HIV infection. <i>Aids</i> , 2008, 22, 2441-2450.	1.0	26
96	Rates and Determinants of Virologic and Immunological Response to HAART Resumption After Treatment Interruption in HIV-1 Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 492-498.	0.9	11
97	Acute Effects of Ambient Particulate Matter on Mortality in Europe and North America: Results from the APHENA Study. <i>Environmental Health Perspectives</i> , 2008, 116, 1480-1486.	2.8	331
98	Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. <i>Aids</i> , 2007, 21, 1283-1291.	1.0	26
99	Short-Term Effects of Carbon Monoxide on Mortality: An Analysis within the APHEA Project. <i>Environmental Health Perspectives</i> , 2007, 115, 1578-1583.	2.8	87
100	Robustness of a parametric model for informatively censored bivariate longitudinal data under misspecification of its distributional assumptions: A simulation study. <i>Statistics in Medicine</i> , 2007, 26, 5473-5485.	0.8	7
101	Seasonal confounding in air pollution and health time-series studies: effect on air pollution effect estimates. <i>Statistics in Medicine</i> , 2006, 25, 4164-4178.	0.8	60
102	Short-term effects of nitrogen dioxide on mortality: an analysis within the APHEA project. <i>European Respiratory Journal</i> , 2006, 27, 1129-1138.	3.1	261
103	Short-Term Effects of Air Pollution on Total and Cardiovascular Mortality. <i>Epidemiology</i> , 2005, 16, 49-57.	1.2	43
104	Association of Clinical Progression in Classic Kaposi's Sarcoma With Reduction of Peripheral B Lymphocytes and Partial Increase in Serum Immune Activation Markers. <i>Archives of Dermatology</i> , 2005, 141, 1421-6.	1.7	18
105	Bivariate modelling of longitudinal measurements of two human immunodeficiency type 1 disease progression markers in the presence of informative drop-outs. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2005, 54, 405-423.	0.5	20
106	Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. <i>Journal of Viral Hepatitis</i> , 2005, 12, 543-550.	1.0	29
107	Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients. <i>Haemophilia</i> , 2005, 11, 360-365.	1.0	7
108	MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2005, 11, 3099.	1.4	81

#	ARTICLE	IF	CITATIONS
109	Estimating the Exposure-Response Relationships between Particulate Matter and Mortality within the APHEA Multicity Project. <i>Environmental Health Perspectives</i> , 2005, 113, 88-95.	2.8	263
110	Acute Effects of Ozone on Mortality from the Air Pollution and Health. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1080-1087.	2.5	397
111	Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. <i>Aids</i> , 2004, 18, 2261-2267.	1.0	44
112	Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. <i>Journal of Viral Hepatitis</i> , 2004, 11, 366-374.	1.0	44
113	Analysis of health outcome time series data in epidemiological studies. <i>Environmetrics</i> , 2004, 15, 101-117.	0.6	88
114	Changes in T Cell Receptor Excision DNA Circle (TREC) Levels in HIV Type 1-Infected Subjects Pre- and Post-Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 47-54.	0.5	10
115	Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. <i>Aids</i> , 2004, 18, 1697-1705.	1.0	56
116	A comparison of two methods for the estimation of precision with incomplete longitudinal data, jointly modelled with a time-to-event outcome. <i>Statistics in Medicine</i> , 2003, 22, 3161-3175.	0.8	12
117	Investigating the dose-response relation between air pollution and total mortality in the APHEA-2 multicity project. <i>Occupational and Environmental Medicine</i> , 2003, 60, 977-982.	1.3	58
118	The temporal pattern of respiratory and heart disease mortality in response to air pollution.. <i>Environmental Health Perspectives</i> , 2003, 111, 1188-1193.	2.8	238
119	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. <i>International Journal of Epidemiology</i> , 2002, 31, 951-958.	0.9	64
120	Quantitation of Human Immunodeficiency Virus Type 1 DNA Forms with the Second Template Switch in Peripheral Blood Cells Predicts Disease Progression Independently of Plasma RNA Load. <i>Journal of Virology</i> , 2002, 76, 10099-10108.	1.5	84
121	Impact of Missing Data Due to Selective Dropouts in Cohort Studies and Clinical Trials. <i>Epidemiology</i> , 2002, 13, 347-355.	1.2	50
122	Significance of immune status, genotype and viral load in the severity of chronic hepatitis C in HIV infected haemophilia patients. <i>Haemophilia</i> , 2002, 8, 668-673.	1.0	12
123	Acute Effects of Particulate Air Pollution on Respiratory Admissions. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 1860-1866.	2.5	566
124	Investigating regional differences in short-term effects of air pollution on daily mortality in the APHEA project: a sensitivity analysis for controlling long-term trends and seasonality.. <i>Environmental Health Perspectives</i> , 2001, 109, 349-353.	2.8	75
125	Confounding and Effect Modification in the Short-Term Effects of Ambient Particles on Total Mortality: Results from 29 European Cities within the APHEA2 Project. <i>Epidemiology</i> , 2001, 12, 521-531.	1.2	810
126	Comparison of smoothing techniques for CD4 data in a Markov model with states defined by CD4: an example on the estimation of the HIV incubation time distribution. <i>Statistics in Medicine</i> , 2001, 20, 3667-3676.	0.8	12

#	ARTICLE	IF	CITATIONS
127	Impact of missing data due to drop-outs on estimators for rates of change in longitudinal studies: a simulation study. <i>Statistics in Medicine</i> , 2001, 20, 3715-3728.	0.8	50
128	Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma. <i>Journal of Virological Methods</i> , 2001, 91, 67-74.	1.0	19
129	Virological and Immunological Response to HAART Therapy in a Community-Based Cohort of HIV-1-Positive Individuals. <i>HIV Clinical Trials</i> , 2001, 2, 6-16.	2.0	15
130	Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. <i>American Journal of Medicine</i> , 2000, 109, 628-634.	0.6	98
131	Effect of recent thymic emigrants on progression of HIV-1 disease. <i>Lancet, The</i> , 2000, 355, 599-604.	6.3	94
132	Natural history of HIV-1 infection. <i>Clinics in Dermatology</i> , 2000, 18, 389-399.	0.8	7
133	The role of immunosuppression and immune-activation in classic Kaposi's sarcoma. , 1999, 82, 817-821.		37
134	Estimation and comparison of rates of change in longitudinal studies with informative drop-outs. , 1999, 18, 1215-1233.		62
135	Estimation and comparison of rates of change in longitudinal studies with informative drop-outs. <i>Statistics in Medicine</i> , 1999, 18, 1215-1233.	0.8	2
136	A survey of bloodborne viruses and associated risk behaviours in Greek prisons. <i>Addiction</i> , 1998, 93, 243-251.	1.7	83
137	Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia. <i>Aids</i> , 1998, 12, 1691-1697.	1.0	39
138	Factors associated with severity and disease progression in chronic hepatitis C. <i>Hepato-Gastroenterology</i> , 1998, 45, 1678-83.	0.5	8
139	Urban air pollution and emergency admissions for asthma in four European cities: the APHEA Project. <i>Thorax</i> , 1997, 52, 760-765.	2.7	251
140	Short-term Effects of Ambient Oxidant Exposure on Mortality: A Combined Analysis within the APHEA Project. <i>American Journal of Epidemiology</i> , 1997, 146, 177-185.	1.6	205
141	Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. <i>European Respiratory Journal</i> , 1997, 10, 1064-1071.	3.1	333
142	Effects of Lead on the Somatic Growth of Children. <i>Archives of Environmental Health</i> , 1997, 52, 377-383.	0.4	52
143	The epidemiologic profile of Kaposi's sarcoma in Greece prior to and during the AIDS era. <i>International Journal of Cancer</i> , 1997, 70, 538-541.	2.3	33
144	Short term effects of air pollution on health: a European approach using epidemiologic time series data: the APHEA protocol.. <i>Journal of Epidemiology and Community Health</i> , 1996, 50, S12-S18.	2.0	313

#	ARTICLE	IF	CITATIONS
145	Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: A case-control study. , 1996, 68, 51-53.		45
146	Daily mortality and "winter type" air pollution in Athens, Greece--a time series analysis within the APHEA project.. Journal of Epidemiology and Community Health, 1996, 50, s47-s51.	2.0	102
147	Methodological issues in studies of air pollution and daily counts of deaths or hospital admissions.. Journal of Epidemiology and Community Health, 1996, 50, S3-11.	2.0	327
148	Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission. European Journal of Gastroenterology and Hepatology, 1996, 8, 469-75.	0.8	4
149	The use of a complex thermohygro-metric index in predicting adverse health effects in Athens. International Journal of Biometeorology, 1995, 38, 194-198.	1.3	10
150	Seasonal Variation of Neonatal and Infant Deaths by Cause in Greece. Scandinavian Journal of Public Health, 1994, 22, 74-80.	0.6	12
151	Short-Term Effects of Air Pollution on Daily Mortality in Athens: A Time-Series Analysis. International Journal of Epidemiology, 1994, 23, 957-967.	0.9	118
152	Attitudes of a Mediterranean population to the truth-telling issue.. Journal of Medical Ethics, 1992, 18, 67-74.	1.0	61
153	Total and cause-specific mortality in a population based cohort of diabetics in Greece. DiabÃ©te & MÃ©tabolisme, 1991, 17, 410-4.	0.3	2
154	Air pollution and cause specific mortality in Athens.. Journal of Epidemiology and Community Health, 1990, 44, 321-324.	2.0	60
155	THE 1987 ATHENS HEATWAVE. Lancet, The, 1988, 332, 573.	6.3	102